Cargando…
Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study
This study aimed to investigate the therapeutic effect of cataract surgery along with simultaneous intravitreal injection (IVI) of aflibercept on diabetic macular edema (DME). This cohort study enrolled 106 patients aged >40 years with type 2 diabetes mellitus and DME who received cataract surger...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387960/ https://www.ncbi.nlm.nih.gov/pubmed/35984152 http://dx.doi.org/10.1097/MD.0000000000030115 |
_version_ | 1784770117306941440 |
---|---|
author | Yen, Chu-Yu Yen, Ju-Chuan Chen, Chun-Chen Hu, Hsiao-Yun Cheng, Feng-Shiang Tseng, Po-Chen |
author_facet | Yen, Chu-Yu Yen, Ju-Chuan Chen, Chun-Chen Hu, Hsiao-Yun Cheng, Feng-Shiang Tseng, Po-Chen |
author_sort | Yen, Chu-Yu |
collection | PubMed |
description | This study aimed to investigate the therapeutic effect of cataract surgery along with simultaneous intravitreal injection (IVI) of aflibercept on diabetic macular edema (DME). This cohort study enrolled 106 patients aged >40 years with type 2 diabetes mellitus and DME who received cataract surgery from January 1, 2016, to October 31, 2020. The baseline and mean data of the following parameters were collected: age, sex, glycated hemoglobin level, diabetic retinopathy (DR) grading, previous DR treatments including IVI of anti–vascular endothelial growth factor and pan-retinal photocoagulation, intraocular pressure, use of intraocular pressure-lowering medication, central subfield thickness (CST), and log MAR visual acuity (VA). Patients were categorized into 2 groups based on whether they received aflibercept IVI or not during cataract surgery and were compared using the t test and Fisher exact test for continuous and discrete variables, respectively. Beta coefficient and standard error were calculated using multiple linear regression analysis to identify the explanatory variables predictive of the net change of CST and log MAR VA. There was no difference in the net change in CST (15.24 ± 45.07 μm vs 18.62 ± 33.84 μm, P = .772) and log MAR VA (−0.27 ± 0.29 vs −0.37 ± 0.31, P = .215). Gender, glycated hemoglobin level, aflibercept IVI during cataract surgery, and baseline CST did not interfere with the morphological and functional outcomes of DME in cataract surgery. Older age was significantly and independently associated with a greater net change in log MAR VA. Proliferative DR was significantly and independently associated with a greater net change in CST and log MAR VA. A greater baseline log MAR VA was significantly and independently associated with lower net change in log MAR VA. Simultaneous aflibercept IVI for treating DME may not interfere with the functional and tomographic parameters of cataract surgery relative to cataract surgery alone. Factors influencing the outcomes of patients with DME undergoing cataract surgery are as follows: age, baseline DR staging, and baseline VA. Identifying these factors of DME preoperatively may be an important consideration in preventing it from progressing and for improving the overall visual prognosis. |
format | Online Article Text |
id | pubmed-9387960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-93879602022-08-23 Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study Yen, Chu-Yu Yen, Ju-Chuan Chen, Chun-Chen Hu, Hsiao-Yun Cheng, Feng-Shiang Tseng, Po-Chen Medicine (Baltimore) Research Article This study aimed to investigate the therapeutic effect of cataract surgery along with simultaneous intravitreal injection (IVI) of aflibercept on diabetic macular edema (DME). This cohort study enrolled 106 patients aged >40 years with type 2 diabetes mellitus and DME who received cataract surgery from January 1, 2016, to October 31, 2020. The baseline and mean data of the following parameters were collected: age, sex, glycated hemoglobin level, diabetic retinopathy (DR) grading, previous DR treatments including IVI of anti–vascular endothelial growth factor and pan-retinal photocoagulation, intraocular pressure, use of intraocular pressure-lowering medication, central subfield thickness (CST), and log MAR visual acuity (VA). Patients were categorized into 2 groups based on whether they received aflibercept IVI or not during cataract surgery and were compared using the t test and Fisher exact test for continuous and discrete variables, respectively. Beta coefficient and standard error were calculated using multiple linear regression analysis to identify the explanatory variables predictive of the net change of CST and log MAR VA. There was no difference in the net change in CST (15.24 ± 45.07 μm vs 18.62 ± 33.84 μm, P = .772) and log MAR VA (−0.27 ± 0.29 vs −0.37 ± 0.31, P = .215). Gender, glycated hemoglobin level, aflibercept IVI during cataract surgery, and baseline CST did not interfere with the morphological and functional outcomes of DME in cataract surgery. Older age was significantly and independently associated with a greater net change in log MAR VA. Proliferative DR was significantly and independently associated with a greater net change in CST and log MAR VA. A greater baseline log MAR VA was significantly and independently associated with lower net change in log MAR VA. Simultaneous aflibercept IVI for treating DME may not interfere with the functional and tomographic parameters of cataract surgery relative to cataract surgery alone. Factors influencing the outcomes of patients with DME undergoing cataract surgery are as follows: age, baseline DR staging, and baseline VA. Identifying these factors of DME preoperatively may be an important consideration in preventing it from progressing and for improving the overall visual prognosis. Lippincott Williams & Wilkins 2022-08-19 /pmc/articles/PMC9387960/ /pubmed/35984152 http://dx.doi.org/10.1097/MD.0000000000030115 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. |
spellingShingle | Research Article Yen, Chu-Yu Yen, Ju-Chuan Chen, Chun-Chen Hu, Hsiao-Yun Cheng, Feng-Shiang Tseng, Po-Chen Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study |
title | Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study |
title_full | Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study |
title_fullStr | Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study |
title_full_unstemmed | Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study |
title_short | Therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: An observational study |
title_sort | therapeutic effect of cataract surgery with simultaneous intravitreal injection of aflibercept on diabetic macular edema: an observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387960/ https://www.ncbi.nlm.nih.gov/pubmed/35984152 http://dx.doi.org/10.1097/MD.0000000000030115 |
work_keys_str_mv | AT yenchuyu therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy AT yenjuchuan therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy AT chenchunchen therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy AT huhsiaoyun therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy AT chengfengshiang therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy AT tsengpochen therapeuticeffectofcataractsurgerywithsimultaneousintravitrealinjectionofafliberceptondiabeticmacularedemaanobservationalstudy |